nach oben

Seminars in Immunopathology

Erschienen in:

01.03.2013 | Review

Inflammation and colorectal cancer: colitis-associated neoplasia

verfasst von: Sergei I. Grivennikov

Erschienen in: Seminars in Immunopathology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Connection between inflammation and cancer is a rapidly developing field. Epidemiological data suggests that inflammation along with distinct arms of host immune system plays a very important role in the development and progression of many different cancers. Inflammatory bowel disease (IBD) is an important risk factor for the development of colon cancer, namely, colitis-associated cancer (CAC). The molecular mechanisms by which inflammation promotes cancer development are still being uncovered and may differ between CAC and other forms of colorectal cancer. Recent work has shed light on the role of distinct immune cells, cytokines, and other immune mediators in virtually all of the steps of colonic tumorigenesis, including tumor initiation and promotion as well as progression and metastasis. The close proximity of colonic tumors to the myriad of intestinal microbes, as well as instrumental role of microbiota in IBD, introduces microbes as new players capable of triggering inflammation and possibly promoting tumorigenesis. Various mechanisms of CAC tumorigenesis as well as new possible hints for the future approaches for prevention and therapy are discussed in this review.

Tenesa A, Dunlop MG (2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 10(6):353–358PubMedCrossRef

Rustgi AK (2007) The genetics of hereditary colon cancer. Genes Dev 21:2525–2538PubMedCrossRef

Feagins LA, Souza RF, Spechler SJ (2009) Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 6:297–305PubMedCrossRef

Saleh M, Trinchieri G (2011) Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 11:9–20PubMedCrossRef

Rubin DC, Shaker A, Levin MS (2012) Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 3:107PubMed

Lakatos PL, Lakatos L (2008) Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 14:3937–3947PubMedCrossRef

Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526–535PubMedCrossRef

Canavan C, Abrams KR, Mayberry J (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 23:1097–1104PubMedCrossRef

Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M (2012) Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 143(2):375–381PubMedCrossRef

10.

Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F (2012) Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 143(2):382–389PubMedCrossRef

11.

Nguyen GC, Bressler B (2012) A tale of two cohorts: are we overestimating the risk of colorectal cancer in inflammatory bowel disease? Gastroenterology 143(2):288–290PubMedCrossRef

12.

Rubin DT, Cruz-Correa MR, Gasche C, Jass JR, Lichtenstein GR, Montgomery EA et al (2008) Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 14:265–274PubMedCrossRef

13.

Neumann H, Vieth M, Langner C, Neurath MF, Mudter J (2011) Cancer risk in IBD: how to diagnose and how to manage DALM and ALM. World J Gastroenterol 17:3184–3191PubMedCrossRef

14.

Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S (1996) Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39:87–92PubMedCrossRef

15.

Neufert C, Becker C, Neurath MF (2007) An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2:1998–2004PubMedCrossRef

16.

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899PubMedCrossRef

17.

Grivennikov SI, Karin M (2010) Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 20:65–71PubMedCrossRef

18.

Trinchieri G (2012) Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol 30:677–706PubMedCrossRef

19.

Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767PubMedCrossRef

20.

Schneikert J, Behrens J (2007) The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 56:417–425PubMedCrossRef

21.

Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW et al (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science 275:1784–1787PubMedCrossRef

22.

Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787–1790PubMedCrossRef

23.

Bienz M, Clevers H (2000) Linking colorectal cancer to Wnt signaling. Cell 103:311–320PubMedCrossRef

24.

Taketo MM, Edelmann W (2009) Mouse models of colon cancer. Gastroenterology 136:780–798PubMedCrossRef

25.

Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M et al (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457:608–611PubMedCrossRef

26.

Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT et al (2009) Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457:603–607PubMedCrossRef

27.

Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138:2101–2114, e2105PubMedCrossRef

28.

Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al (2004) IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296PubMedCrossRef

29.

Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816PubMedCrossRef

30.

Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S, Wang J et al (2001) Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 22:665–671PubMedCrossRef

31.

Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G et al (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Investig 98:1010–1020PubMedCrossRef

32.

Kaler P, Godasi BN, Augenlicht L, Klampfer L (2009) The NF-kappaB/AKT-dependent induction of Wnt signaling in colon cancer cells by macrophages and IL-1beta. Cancer Microenviron 2(1):69–80

33.

Brown JB, Lee G, Managlia E, Grimm GR, Dirisina R, Goretsky T et al (2010) Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology 138:595–605, 605 e591-593PubMedCrossRef

34.

Lee G, Goretsky T, Managlia E, Dirisina R, Singh AP, Brown JB et al (2010) Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 139:869–881, 881 e861-869PubMedCrossRef

35.

Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S et al (2008) Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J 27:1671–1681PubMedCrossRef

36.

Tessner TG, Muhale F, Riehl TE, Anant S, Stenson WF (2004) Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 114:1676–1685PubMed

37.

Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM et al (2004) Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 279:29797–29804PubMedCrossRef

38.

Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310:1504–1510PubMedCrossRef

39.

Westbrook AM, Wei B, Braun J, Schiestl RH (2009) Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res 69:4827–4834PubMedCrossRef

40.

Westbrook AM, Schiestl RH (2010) Atm-deficient mice exhibit increased sensitivity to dextran sulfate sodium-induced colitis characterized by elevated DNA damage and persistent immune activation. Cancer Res 70:1875–1884PubMedCrossRef

41.

Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D et al (2008) DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 118:2516–2525PubMed

42.

Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. Nat Rev Cancer 3:276–285PubMedCrossRef

43.

Olipitz W, Wiktor-Brown D, Shuga J, Pang B, McFaline J, Lonkar P et al (2012) Integrated molecular analysis indicates undetectable DNA damage in mice after continuous irradiation at ~400-fold natural background radiation. Environ Health Perspect 120(8):1130–1136

44.

Mangerich A, Knutson CG, Parry NM, Muthupalani S, Ye W, Prestwich E et al (2012) Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer. Proc Natl Acad Sci U S A 109:E1820–E1829PubMedCrossRef

45.

Kraus S, Arber N (2009) Inflammation and colorectal cancer. Curr Opin Pharmacol 9(4):405–410PubMedCrossRef

46.

Boulard O, Kirchberger S, Royston DJ, Maloy KJ, Powrie FM (2012) Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. J Exp Med 209:1309–1324PubMedCrossRef

47.

Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, Feng Y et al (2003) CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 63:6042–6050PubMed

48.

Erdman SE, Sohn JJ, Rao VP, Nambiar PR, Ge Z, Fox JG et al (2005) CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65:3998–4004PubMedCrossRef

49.

Garrett WS, Punit S, Gallini CA, Michaud M, Zhang D, Sigrist KS et al (2009) Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16:208–219PubMedCrossRef

50.

Shaked H, Hofseth LJ, Chumanevich A, Chumanevich AA, Wang J, Wang Y et al (2012) Chronic epithelial NF-kappaB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci U S A 109:14007–14012PubMedCrossRef

51.

Erdman SE, Rao VP, Poutahidis T, Rogers AB, Taylor CL, Jackson EA et al (2009) Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proc Natl Acad Sci U S A 106:1027–1032PubMedCrossRef

52.

Goodman JE, Hofseth LJ, Hussain SP, Harris CC (2004) Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 44:3–9PubMedCrossRef

53.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081PubMedCrossRef

54.

Vong LB, Tomita T, Yoshitomi T, Matsui H, Nagasaki Y (2012) An orally administered redox nanoparticle that accumlates in the colonic mucosa and reduces colitis in mice. Gastroenterology 143(4):1027–1036.e3PubMedCrossRef

55.

Shimizu T, Marusawa H, Endo Y, Chiba T (2012) Inflammation-mediated genomic instability: roles of activation-induced cytidine deaminase in carcinogenesis. Cancer Sci 103(7):1201–1206

56.

Takai A, Marusawa H, Minaki Y, Watanabe T, Nakase H, Kinoshita K et al (2012) Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation. Oncogene 31:1733–1742PubMedCrossRef

57.

Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T et al (2006) The colorectal microRNAome. Proc Natl Acad Sci U S A 103:3687–3692PubMedCrossRef

58.

Grady WM, Carethers JM (2008) Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135:1079–1099PubMedCrossRef

59.

Oving IM, Clevers HC (2002) Molecular causes of colon cancer. Eur J Clin Invest 32:448–457PubMedCrossRef

60.

Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H et al (2007) Transcriptome profile of human colorectal adenomas. Mol Cancer Res 5:1263–1275PubMedCrossRef

61.

Perucho M (2003) Tumors with microsatellite instability: many mutations, targets and paradoxes. Oncogene 22:2223–2225PubMedCrossRef

62.

Foran E, Garrity-Park MM, Mureau C, Newell J, Smyrk TC, Limburg PJ et al (2010) Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6. Mol Cancer Res: MCR 8:471–481PubMedCrossRef

63.

Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, de Haar C, van der Woude CJ (2012) IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis 33(10):1889–1896

64.

Hartnett L, Egan LJ (2012) Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 33:723–731PubMedCrossRef

65.

Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD et al (2008) Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 68:10280–10289PubMedCrossRef

66.

Eads CA, Nickel AE, Laird PW (2002) Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic mice. Cancer Res 62:1296–1299PubMed

67.

Yang L, Belaguli N, Berger DH (2009) MicroRNA and colorectal cancer. World J Surg 33:638–646PubMedCrossRef

68.

Boldin MP, Baltimore D (2012) MicroRNAs, new effectors and regulators of NF-kappaB. Immunol Rev 246:205–220PubMedCrossRef

69.

Kanaan Z, Rai SN, Eichenberger MR, Barnes C, Dworkin AM, Weller C et al (2012) Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat 33:551–560PubMedCrossRef

70.

Kuraishy A, Karin M, Grivennikov SI (2011) Tumor promotion via injury- and death-induced inflammation. Immunity 35:467–477PubMedCrossRef

71.

Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21:11–19PubMedCrossRef

72.

Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15:91–102PubMedCrossRef

73.

Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103–113PubMedCrossRef

74.

Schiechl G, Bauer B, Fuss I, Lang SA, Moser C, Ruemmele P et al (2011) Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest 121:1692–1708PubMedCrossRef

75.

Tanaka T, Kohno H, Suzuki R, Hata K, Sugie S, Niho N et al (2006) Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer 118:25–34PubMedCrossRef

76.

Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 94:965–973PubMedCrossRef

77.

Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR et al (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016–1022PubMedCrossRef

78.

Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1:11–21PubMedCrossRef

79.

Chung DC (2000) The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 119:854–865PubMedCrossRef

80.

Rogler G, Andus T (1998) Cytokines in inflammatory bowel disease. World J Surg 22:382–389PubMedCrossRef

81.

Greten FR, Karin M (2005) NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759PubMedCrossRef

82.

Ben-Neriah Y, Karin M (2011) Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12:715–723PubMedCrossRef

83.

Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W (1996) Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2:998–1004PubMedCrossRef

84.

Majumdar S, Aggarwal BB (2001) Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 167:2911–2920PubMed

85.

Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431–436PubMedCrossRef

86.

Eckmann L, Nebelsiek T, Fingerle AA, Dann SM, Mages J, Lang R et al (2008) Opposing functions of IKKbeta during acute and chronic intestinal inflammation. Proc Natl Acad Sci U S A 105:15058–15063PubMedCrossRef

87.

Wang S, Liu Z, Wang L, Zhang X (2009) NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 6:327–334PubMedCrossRef

88.

Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S et al (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118:560–570PubMed

89.

Kollias G (2004) Modeling the function of tumor necrosis factor in immune pathophysiology. Autoimmun Rev 3(Suppl 1):S24–S25PubMed

90.

Atreya R, Neurath MF (2008) New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol 1:175–182PubMedCrossRef

91.

Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809PubMedCrossRef

92.

Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M et al (2009) STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 206:1465–1472PubMedCrossRef

93.

Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR (2007) Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 21:1396–1408PubMedCrossRef

94.

Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z et al (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15:283–293PubMedCrossRef

95.

Bollrath J, Greten FR (2009) IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 10:1314–1319PubMedCrossRef

96.

Rose-John S, Scheller J, Elson G, Jones SA (2006) Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80:227–236PubMedCrossRef

97.

Scheller J, Rose-John S (2006) Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 195:173–183PubMedCrossRef

98.

Kishimoto T (2005) Interleukin-6: from basic science to medicine—40 years in immunology. Annu Rev Immunol 23:1–21PubMedCrossRef

99.

Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S et al (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 6:583–588PubMedCrossRef

100.

Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M et al (1999) Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 94:2156–2164PubMedCrossRef

101.

Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A et al (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126:989–996, discussion 947PubMedCrossRef

102.

Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J et al (2007) Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol 179:2041–2045PubMed

103.

Atreya R, Neurath MF (2008) Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets 9:369–374PubMedCrossRef

104.

Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238PubMedCrossRef

105.

Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR et al (2005) IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4:217–220PubMedCrossRef

106.

Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A et al (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491–501PubMedCrossRef

107.

Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ et al (2002) Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 8:1089–1097PubMedCrossRef

108.

Gerlach K, Daniel C, Lehr HA, Nikolaev A, Gerlach T, Atreya R et al (2012) Transcription factor NFATc2 controls the emergence of colon cancer associated with IL-6-dependent colitis. Cancer Res 72(17):4340–4350PubMedCrossRef

109.

Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1):i104–i108PubMedCrossRef

110.

Putoczki T, Ernst M (2010) More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol. doi:10.1186/1747-1028-5-14

111.

Waldner MJ, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R et al (2010) VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 207:2855–2868PubMedCrossRef

112.

Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS et al (2006) IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 203:2485–2494PubMedCrossRef

113.

Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ et al (2010) Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464:1371–1375PubMedCrossRef

114.

Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B et al (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116:1310–1316PubMedCrossRef

115.

Cox JH, Kljavin NM, Ota N, Leonard J, Roose-Girma M, Diehl L et al (2012) Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol 5:99–109PubMedCrossRef

116.

Duerr RH (2007) Genome-wide association studies herald a new era of rapid discoveries in inflammatory bowel disease research. Gastroenterology 132:2045–2049PubMedCrossRef

117.

Wirtz S, Neurath MF (2007) Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 59:1073–1083PubMedCrossRef

118.

Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K et al (2006) IL-23 promotes tumour incidence and growth. Nature 442:461–465PubMedCrossRef

119.

Langowski JL, Kastelein RA, Oft M (2007) Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 28:207–212PubMedCrossRef

120.

Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, Williams BO et al (2007) Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 67:9721–9730PubMedCrossRef

121.

Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Österreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature doi:10.1038/nature11465

122.

Hyun YS, Han DS, Lee AR, Eun CS, Youn J, Kim HY (2012) Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 33:931–936PubMedCrossRef

123.

Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O, Bothwell AL (2010) Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci U S A 107:5540–5544PubMedCrossRef

124.

Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L et al (2008) Regulation of inflammatory responses by IL-17F. J Exp Med 205:1063–1075PubMedCrossRef

125.

Chae WJ, Bothwell AL (2011) IL-17F deficiency inhibits small intestinal tumorigenesis in ApcMin/+ mice. Biochem Biophys Res Commun 414:31–36PubMedCrossRef

126.

Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y et al (2012) A protective role by interleukin-17F in colon tumorigenesis. PLoS One 7:e34959PubMedCrossRef

127.

Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C et al (2009) RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136:257–267PubMedCrossRef

128.

Kesselring R, Jauch D, Fichtner-Feigl S (2012) Interleukin 21 impairs tumor immunosurveillance of colitis-associated colorectal cancer. Oncoimmunology 1:537–538PubMedCrossRef

129.

Stolfi C, Rizzo A, Franze E, Rotondi A, Fantini MC, Sarra M et al (2011) Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med 208:2279–2290PubMedCrossRef

130.

Jauch D, Martin M, Schiechl G, Kesselring R, Schlitt HJ, Geissler EK et al (2011) Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut 60:1678–1686PubMedCrossRef

131.

Rakoff-Nahoum S, Medzhitov R (2007) Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317:124–127PubMedCrossRef

132.

Rakoff-Nahoum S, Medzhitov R (2008) Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc) 73:555–561CrossRef

133.

Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM et al (2010) MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 207:1625–1636PubMedCrossRef

134.

Normand S, Delanoye-Crespin A, Bressenot A, Huot L, Grandjean T, Peyrin-Biroulet L et al (2011) Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci U S A 108:9601–9606PubMedCrossRef

135.

Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB et al (2010) The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 207:1045–1056PubMedCrossRef

136.

Allen IC, Wilson JE, Schneider M, Lich JD, Roberts RA, Arthur JC et al (2012) NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity 36:742–754PubMedCrossRef

137.

Wan YY, Flavell RA (2008) TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol 28:647–659PubMedCrossRef

138.

Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C (2009) Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 4:e6026PubMedCrossRef

139.

Fantini MC, Rizzo A, Fina D, Caruso R, Sarra M, Stolfi C et al (2009) Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 136(1308–1316):e1301–e1303

140.

Rizzo A, Waldner MJ, Stolfi C, Sarra M, Fina D, Becker C et al (2011) Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res 71:7423–7432PubMedCrossRef

141.

Dube PE, Yan F, Punit S, Girish N, McElroy SJ, Washington MK et al (2012) Epidermal growth factor receptor inhibits colitis-associated cancer in mice. J Clin Invest 122(8):2780–2792PubMedCrossRef

142.

Cohen DJ, Hochster HS (2008) Rationale for combining biotherapy in the treatment of advanced colon cancer. Gastrointest Cancer Res 2:145–151PubMed

143.

Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134:577–594PubMedCrossRef

144.

Blaser MJ (2010) Harnessing the power of the human microbiome. Proc Natl Acad Sci U S A 107:6125–6126PubMedCrossRef

145.

Othman M, Aguero R, Lin HC (2008) Alterations in intestinal microbial flora and human disease. Curr Opin Gastroenterol 24:11–16PubMedCrossRef

146.

Guarner F, Malagelada JR (2003) Gut flora in health and disease. Lancet 361:512–519PubMedCrossRef

147.

Rowland IR (2009) The role of the gastrointestinal microbiota in colorectal cancer. Curr Pharm Des 15:1524–1527PubMedCrossRef

148.

Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D et al (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461:1282–1286PubMedCrossRef

149.

Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS et al (2006) Metagenomic analysis of the human distal gut microbiome. Science 312:1355–1359PubMedCrossRef

150.

Cho I, Blaser MJ (2012) The human microbiome: at the interface of health and disease. Nat Rev Genet 13:260–270PubMed

151.

Li Y, Kundu P, Seow SW, de Matos CT, Aronsson L, Chin KC et al (2012) Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis 33:1231–1238PubMedCrossRef

152.

Dove WF, Clipson L, Gould KA, Luongo C, Marshall DJ, Moser AR et al (1997) Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res 57:812–814PubMed

153.

Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U et al (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:485–498PubMedCrossRef

154.

Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB et al (2008) Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4:337–349PubMedCrossRef

155.

Kim SC, Tonkonogy SL, Karrasch T, Jobin C, Sartor RB (2007) Dual-association of gnotobiotic IL-10−/− mice with 2 nonpathogenic commensal bacteria induces aggressive pancolitis. Inflamm Bowel Dis 13:1457–1466PubMedCrossRef

156.

Kullberg MC, Ward JM, Gorelick PL, Caspar P, Hieny S, Cheever A et al (1998) Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect Immun 66:5157–5166PubMed

157.

Mazmanian SK, Round JL, Kasper DL (2008) A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620–625PubMedCrossRef

158.

Round JL, Mazmanian SK (2009) The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9:313–323PubMedCrossRef

159.

Round JL, O'Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 34:J220–J225PubMedCrossRef

160.

Arthur JC, Jobin C (2011) The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis 17:396–409PubMedCrossRef

161.

Strober W, Fuss IJ (2006) Experimental models of mucosal inflammation. Adv Exp Med Biol 579:55–97PubMedCrossRef

162.

Kolida S, Gibson GR (2011) Synbiotics in health and disease. Annu Rev Food Sci Technol 2:373–393PubMedCrossRef

163.

Chichlowski M, Sharp JM, Vanderford DA, Myles MH, Hale LP (2008) Helicobacter typhlonius and Helicobacter rodentium differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL10-deficient mice. Comp Med 58:534–541PubMed

164.

Newman JV, Kosaka T, Sheppard BJ, Fox JG, Schauer DB (2001) Bacterial infection promotes colon tumorigenesis in Apc(Min/+) mice. J Infect Dis 184:227–230PubMedCrossRef

165.

Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S et al (2007) Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 5:345–351PubMedCrossRef

166.

Strober W, Fuss I, Mannon P (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117:514–521PubMedCrossRef

167.

Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP et al (2012) Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336:1314–1317PubMedCrossRef

168.

Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC (2008) The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 105:15064–15069PubMedCrossRef

169.

Petersson J, Schreiber O, Hansson GC, Gendler SJ, Velcich A, Lundberg JO et al (2011) Importance and regulation of the colonic mucus barrier in a mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 300:G327–G333PubMedCrossRef

170.

Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB et al (2006) Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131:117–129PubMedCrossRef

171.

Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S et al (2002) Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295:1726–1729PubMedCrossRef

172.

Yang K, Popova NV, Yang WC, Lozonschi I, Tadesse S, Kent S et al (2008) Interaction of Muc2 and Apc on Wnt signaling and in intestinal tumorigenesis: potential role of chronic inflammation. Cancer Res 68:7313–7322PubMedCrossRef

173.

Khounlotham M, Kim W, Peatman E, Nava P, Medina-Contreras O, Addis C (2012) Compromised intestinal epithelial barrier induces adaptive immune compensation that protects from colitis. Immunity 37(3):563–573PubMedCrossRef

174.

Iacucci M, Ghosh S (2011) Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol 4:129–143PubMedCrossRef

175.

Kiesslich R, Goetz M, Angus EM, Hu Q, Guan Y, Potten C et al (2007) Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology 133:1769–1778PubMedCrossRef

176.

Kiesslich R, Duckworth CA, Moussata D, Gloeckner A, Lim LG, Goetz M et al (2012) Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 61:1146–1153PubMedCrossRef

177.

Sonnenberg GF, Monticelli LA, Alenghat T, Fung TC, Hutnick NA, Kunisawa J et al (2012) Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 336:1321–1325PubMedCrossRef

178.

Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B (2012) Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 56:1283–1292PubMedCrossRef

179.

Seki E, Schnabl B (2012) Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 590:447–458PubMedCrossRef

180.

Yan AW, Schnabl B (2012) Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol 4:110–118PubMedCrossRef

181.

Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ et al (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338(6103):120–123

182.

Scanlan PD, Shanahan F, Clune Y, Collins JK, O'Sullivan GC, O'Riordan M et al (2008) Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol 10:789–798PubMedCrossRef

183.

Nanau RM, Neuman MG (2012) Metabolome and inflammasome in inflammatory bowel disease. Transl Res 160:1–28PubMedCrossRef

184.

Neuman MG, Nanau RM (2012) Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res 160:29–44PubMedCrossRef

185.

Blumberg R, Powrie F (2012) Microbiota, disease, and back to health: a metastable journey. Sci Transl Med 4:137rv137CrossRef

186.

Garrett WS, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML et al (2010) Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8:292–300PubMedCrossRef

187.

Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S et al (2007) Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131:33–45PubMedCrossRef

188.

Vijay-Kumar M, Sanders CJ, Taylor RT, Kumar A, Aitken JD, Sitaraman SV et al (2007) Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 117:3909–3921PubMed

189.

Chamaillard M, Dessein R (2011) Defensins couple dysbiosis to primary immunodeficiency in Crohn's disease. World J Gastroenterol 17:567–571PubMedCrossRef

190.

Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T et al (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482:179–185PubMed

191.

Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ et al (2011) NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145:745–757PubMedCrossRef

192.

Hu B, Elinav E, Flavell RA (2011) Inflammasome-mediated suppression of inflammation-induced colorectal cancer progression is mediated by direct regulation of epithelial cell proliferation. Cell Cycle 10:1936–1939PubMedCrossRef

193.

Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C et al (2010) Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A 107:21635–21640PubMedCrossRef

194.

Chen GY, Shaw MH, Redondo G, Nunez G (2008) The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 68:10060–10067PubMedCrossRef

195.

Ayres JS, Trinidad NJ, Vance RE (2012) Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med 18:799–806PubMedCrossRef

196.

Zakostelska Z, Kverka M, Klimesova K, Rossmann P, Mrazek J, Kopecny J et al (2011) Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One 6:e27961PubMedCrossRef

197.

Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L et al (2011) The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 8:110–120PubMedCrossRef

198.

Kverka M, Zakostelska Z, Klimesova K, Sokol D, Hudcovic T, Hrncir T et al (2011) Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol 163:250–259PubMedCrossRef

199.

Appleyard CB, Cruz ML, Isidro AA, Arthur JC, Jobin C, De Simone C (2011) Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer. Am J Physiol Gastrointest Liver Physiol 301:G1004–G1013PubMedCrossRef

200.

Uronis JM, Arthur JC, Keku T, Fodor A, Carroll IM, Cruz ML et al (2011) Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis 17:289–297PubMedCrossRef

201.

Weissman JS, Coyle W (2012) Stool transplants: ready for prime time? Curr Gastroenterol Rep 14(4):313–316

202.

El-Matary W, Simpson R, Ricketts-Burns N (2012) Fecal microbiota transplantation: are we opening a can of worms? Gastroenterology 143(2):e19PubMedCrossRef

203.

Brandt LJ (2012) Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterol Hepatol (N Y) 8:191–194

204.

Holmes E, Kinross J, Gibson GR, Burcelin R, Jia W, Pettersson S et al (2012) Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med 4:137rv136CrossRef

205.

Rabizadeh S, Rhee KJ, Wu S, Huso D, Gan CM, Golub JE et al (2007) Enterotoxigenic bacteroides fragilis: a potential instigator of colitis. Inflamm Bowel Dis 13:1475–1483PubMedCrossRef

206.

Huycke MM, Abrams V, Moore DR (2002) Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis 23:529–536PubMedCrossRef

207.

Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R et al (2011) Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 17:1971–1978PubMedCrossRef

208.

Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R et al (2011) Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 17(9):1971–1978PubMedCrossRef

209.

Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM et al (2012) Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 22:292–298PubMedCrossRef

210.

Yang L, Pei Z (2006) Bacteria, inflammation, and colon cancer. World J Gastroenterol 12:6741–6746PubMed

211.

Sears CL, Pardoll DM (2011) Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis 203:306–311PubMedCrossRef

212.

Klampfer L (2008) The role of signal transducers and activators of transcription in colon cancer. Front Biosci 13:2888–2899PubMedCrossRef

213.

Wu Y, Zhou BP (2009) Inflammation: a driving force speeds cancer metastasis. Cell Cycle 8(20):3267–3273PubMedCrossRef

214.

Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420–1428PubMedCrossRef

215.

Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818–829PubMedCrossRef

216.

Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP (2009) Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15:416–428PubMedCrossRef

217.

Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y et al (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 100:2645–2650PubMedCrossRef

218.

Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6:297–305PubMedCrossRef

219.

Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A (2009) Chemokines and chemokine receptors: an overview. Front Biosci 14:540–551PubMedCrossRef

220.

Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A et al (2012) Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 22:91–105PubMedCrossRef

221.

Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23:101–117PubMedCrossRef

222.

Mohammed FF, Smookler DS, Taylor SE, Fingleton B, Kassiri Z, Sanchez OH et al (2004) Abnormal TNF activity in Timp3−/− mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet 36:969–977PubMedCrossRef

223.

Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL et al (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446:690–694PubMedCrossRef

Titel: Inflammation and colorectal cancer: colitis-associated neoplasia
verfasst von: Sergei I. Grivennikov
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: Seminars in Immunopathology / Ausgabe 2/2013
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-012-0352-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Multifaceted roles of PGE2 in inflammation and cancer

Mast cells and inflammation-associated colorectal carcinogenesis

Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents

Helicobacter pylori infection and gastric carcinogenesis in rodent models

Protumor and antitumor functions of neutrophil granulocytes